Human Girdin Antibody
R&D Systems, part of Bio-Techne | Catalog # AF5345
Key Product Details
Species Reactivity
Validated:
Human
Cited:
Human, Mouse
Applications
Validated:
Simple Western, Western Blot
Cited:
Immunohistochemistry, Immunohistochemistry-Paraffin, Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Sheep IgG
Product Specifications
Immunogen
E. coli-derived recombinant human Girdin
Asn1510-Leu1824
Accession # Q3V6T2
Asn1510-Leu1824
Accession # Q3V6T2
Specificity
Detects endogenous human Girdin in Western blots.
Clonality
Polyclonal
Host
Sheep
Isotype
IgG
Scientific Data Images for Human Girdin Antibody
Detection of Human Girdin by Western Blot.
Western blot shows lysates of H69AR human small cell lung cancer cell line, MRC-5 human embryonic lung fibroblast cell line, and A431 human epithelial carcinoma cell line. PVDF membrane was probed with 1 µg/mL of Human Girdin Antigen Affinity-purified Polyclonal Antibody (Catalog # AF5345) followed by HRP-conjugated Anti-Sheep IgG Secondary Antibody (HAF016). A specific band was detected for Girdin at approximately 200 to 220 kDa (as indicated). This experiment was conducted using Immunoblot Buffer Group 1.
Detection of Human Girdin by Simple WesternTM.
Simple Western lane view shows lysates of A431 human epithelial carcinoma cell line, loaded at 0.2 mg/mL. A specific band was detected for Girdin at approximately 206 kDa (as indicated) using 10 µg/mL of Sheep Anti-Human Girdin Antigen Affinity-purified Polyclonal Antibody (Catalog # AF5345) followed by 1:50 dilution of HRP-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # HAF016). This experiment was conducted under reducing conditions and using the 66-440kDa separation system.Applications for Human Girdin Antibody
Application
Recommended Usage
Simple Western
10 µg/mL
Sample: A431 human epithelial carcinoma cell line
Sample: A431 human epithelial carcinoma cell line
Western Blot
1 µg/mL
Sample: H69AR human small cell lung cancer cell line, MRC-5 human embryonic lung fibroblast cell line, and A431 human epithelial carcinoma cell line
Sample: H69AR human small cell lung cancer cell line, MRC-5 human embryonic lung fibroblast cell line, and A431 human epithelial carcinoma cell line
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Antigen Affinity-purified
Reconstitution
Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: Girdin
Girdin (GIRDers of actIN filaments; also APE and GIV) is a member of the CCDC88 family of molecules. It is a cytosolic protein, ubiquitously expressed, and plays a key role in the motility of breast cancer cells. Human Girdin is 1871 amino acids (aa) in length. It contains two coiled-coil regions that mediate homodimerization (aa 196-425 and 458-1358), and one phosphoinositide-binding domain (aa 1390-1408). Normally, Girdin is membrane-associated via an interaction with phosphoinositides. Upon phosphorylation at Ser1417 by Akt, it relocates to lamellipodia where it crosslinks actin filaments. Multiple isoforms of Girdin have been detected.
Long Name
Girders of Actin Filament
Alternate Names
APE, CCDC88A, GIV, GRDN, HkRP1
Gene Symbol
CCDC88A
UniProt
Additional Girdin Products
Product Documents for Human Girdin Antibody
Product Specific Notices for Human Girdin Antibody
For research use only
Loading...
Loading...
Loading...
Loading...